Kahn Brothers’s Bristol-Myers Squibb BMY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$10M Buy
174,152
+3,771
+2% +$217K 1.59% 16
2026
Q1
$10.3M Sell
170,381
-31,815
-16% -$1.85M 1.83% 16
2025
Q4
$10.9M Sell
202,196
-70,138
-26% -$3.37M 1.93% 13
2025
Q3
$12.3M Sell
272,334
-278,349
-51% -$13M 2.31% 13
2025
Q2
$25.5M Sell
550,683
-46,745
-8% -$2.29M 5.12% 9
2025
Q1
$36.4M Sell
597,428
-92,824
-13% -$5.41M 7.37% 7
2024
Q4
$39M Sell
690,252
-135,856
-16% -$7.59M 8.48% 4
2024
Q3
$42.7M Sell
826,108
-1,150
-0.1% -$53.9K 7.36% 7
2024
Q2
$34.4M Sell
827,258
-4,733
-0.6% -$212K 5.77% 7
2024
Q1
$45.1M Sell
831,991
-1,925
-0.2% -$98.1K 6.69% 6
2023
Q4
$42.8M Sell
833,916
-17,783
-2% -$933K 6.74% 7
2023
Q3
$49.5M Sell
851,699
-19,545
-2% -$1.2M 7.72% 7
2023
Q2
$61.3M Sell
871,244
-29,312
-3% -$1.97M 8.99% 4
2023
Q1
$62.4M Sell
900,556
-13,445
-1% -$948K 8.98% 3
2022
Q4
$65.8M Sell
914,001
-10,092
-1% -$761K 8.66% 5
2022
Q3
$65.7M Sell
924,093
-4,772
-0.5% -$346K 10.24% 1
2022
Q2
$71.5M Buy
928,865
+3,137
+0.3% +$239K 9.63% 3
2022
Q1
$67.6M Buy
925,728
+4,125
+0.4% +$277K 8.58% 4
2021
Q4
$57.5M Buy
921,603
+47,873
+5% +$2.81M 7.89% 7
2021
Q3
$51.7M Sell
873,730
-19,315
-2% -$1.27M 7.28% 9
2021
Q2
$58.3M Buy
893,045
+46,709
+6% +$3.05M 8.35% 3
2021
Q1
$53.4M Sell
846,336
-17,901
-2% -$1.11M 8.27% 5
2020
Q4
$53.6M Sell
864,237
-71,740
-8% -$4.41M 9.35% 2
2020
Q3
$56.4M Sell
935,977
-79,827
-8% -$4.8M 10.7% 2
2020
Q2
$59.7M Sell
1,015,804
-10,405
-1% -$622K 10.09% 3
2020
Q1
$57.2M Sell
1,026,209
-27,523
-3% -$1.68M 10.46% 3
2019
Q4
$67.6M Sell
1,053,732
-19,028
-2% -$1.09M 8.2% 5
2019
Q3
$54.4M Buy
1,072,760
+54,480
+5% +$2.56M 6.82% 8
2019
Q2
$46.2M Buy
1,018,280
+513,930
+102% +$23.9M 5.77% 9
2019
Q1
$24.1M Buy
504,350
+484,400
+2,428% +$24.1M 3.76% 10
2018
Q4
$1.04M Hold
19,950
0.19% 24
2018
Q3
$1.24M Hold
19,950
0.19% 24
2018
Q2
$1.1M Buy
19,950
+200
+1% +$10.8K 0.18% 24
2018
Q1
$1.25M Buy
19,750
+700
+4% +$45K 0.2% 24
2017
Q4
$1.17M Hold
19,050
0.18% 24
2017
Q3
$1.21M Sell
19,050
-533
-3% -$31.1K 0.19% 24
2017
Q2
$1.09M Sell
19,583
-9,000
-31% -$490K 0.17% 25
2017
Q1
$1.55M Hold
28,583
0.27% 23
2016
Q4
$1.67M Hold
28,583
0.28% 23
2016
Q3
$1.54M Hold
28,583
0.28% 23
2016
Q2
$2.1M Hold
28,583
0.41% 23
2016
Q1
$1.83M Buy
28,583
+533
+2% +$33.6K 0.34% 23
2015
Q4
$1.93M Sell
28,050
-750
-3% -$49.6K 0.34% 24
2015
Q3
$1.7M Hold
28,800
0.32% 24
2015
Q2
$1.92M Buy
28,800
+400
+1% +$26.4K 0.32% 23
2015
Q1
$1.83M Hold
28,400
0.31% 23
2014
Q4
$1.68M Buy
28,400
+750
+3% +$42.3K 0.29% 24
2014
Q3
$1.42M Hold
27,650
0.23% 27
2014
Q2
$1.34M Sell
27,650
-2,000
-7% -$98.6K 0.2% 25
2014
Q1
$1.54M Buy
29,650
+2,000
+7% +$106K 0.22% 23
2013
Q4
$1.47M Sell
27,650
-650
-2% -$33.1K 0.25% 24
2013
Q3
$1.31M Sell
28,300
-27,133
-49% -$1.19M 0.19% 28
2013
Q2
$2.48M Buy
+55,433
New +$2.41M 0.38% 21

Other funds holding BMY

Kahn Brothers's BMY Position: Q2 2026 in Review

Kahn Brothers increased its Bristol-Myers Squibb (BMY) stake by 2.2% in Q2 2026, buying an estimated $217K and bringing the position to 174,152 shares worth $10M. The position accounts for 1.59% of the portfolio, ranked #16.

Kahn Brothers first reported a position in BMY in Q2 2013 and has held it in 53 quarters since. The position peaked at $71.5M in Q2 2022. 2,506 funds tracked by Wall St. Rank hold BMY as of Q2 2026.

  • Kahn Brothers held 174,152 shares of Bristol-Myers Squibb worth $10M as of Q2 2026.
  • Kahn Brothers bought 3,771 Bristol-Myers Squibb shares in Q2 2026, an estimated $217K.
  • Bristol-Myers Squibb made up 1.59% of Kahn Brothers's portfolio in Q2 2026, its #16 holding.
  • Kahn Brothers first reported a position in Bristol-Myers Squibb in Q2 2013 and has held it in 53 quarters since.
  • Kahn Brothers's Bristol-Myers Squibb position peaked at $71.5M in Q2 2022.
  • 2,506 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.

Based on Kahn Brothers Group's 13F filing for Q2 2026, filed 14 Aug 2026.